HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $25 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.9%

Neg 0% Neu 86.9% Pos 0%

HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $25 price target.